articleThe Lancet Respiratory MedicineJan 31, 2025GREEN OA

Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials

German Center for Lung Research · Baylor College of Medicine · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

58
total citations
FWCI
65.91
Percentile
100%
References
29
Citations per year

Authors

16

Topics & keywords

Keywords
  • Medicine
  • Placebo
  • Dupilumab
  • Pulmonary disease
  • Internal medicine
  • Double blind
  • Inflammation
  • Randomized controlled trial
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding